OncoCyte (OCX)
(Delayed Data from NSDQ)
$3.34 USD
+0.34 (11.33%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.34 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
OCX 3.34 +0.34(11.33%)
Will OCX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for OCX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for OCX
CareDx (CDNA) Reports Q2 Loss, Tops Revenue Estimates
Surgery Partners (SGRY) Q1 Earnings and Revenues Beat Estimates
OCX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Elevance Health (ELV) Tops Q1 Earnings and Revenue Estimates
3 Medical Services Stocks to Buy Amid Industry Challenges
Life Time Group Holdings, Inc. (LTH) Tops Q4 Earnings and Revenue Estimates
Other News for OCX
PRISM MarketView Features Oncocyte CFO Andrea S. James on Her Career and Leadership in Molecular Diagnostics Technology
Oncocyte?s VitaGraft? Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study
OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript
OncoCyte’s Growth Potential and Strategic Positioning Bolster Buy Rating
OncoCyte’s New Sales Agreement and Termination of Old Deal